Novel Pt(IV) prodrug self-assembled nanoparticles with enhanced blood circulation stability and improved antitumor capacity of oxaliplatin for cancer therapy

References

• Ding F, Zhang LP, Chen H, et al. (2020). Enhancing chemotherapy efficacy of platium prodrug nanoparticles and inhibiting cancer metastasis via targeting iron homeostasis. Nanoscale Horiz 5:1–10.
   Web of Science ®Google Scholar
• Feng B, Zhou FY, Hou B, et al. (2018). Binary cooperative prodrug nanoparticles improve immunotherapy by synergistically modulating immune tumor microenvironment. Adv Mater 30: e1803001.
   PubMed Web of Science ®Google Scholar
• Gibson D. (2016). Platinum(IV) anticancer prodrugs-hypotheses and facts. Dalton Trans 45:12983–91.
   PubMed Web of Science ®Google Scholar
• He L, Sun M, Cheng X, et al. (2019). H/Redox dual-sensitive platinum(IV)-based micelles with greatly enhanced antitumor effect for combination chemotherapy. J Colloid Interf Sci 541:30–41.
   PubMed Web of Science ®Google Scholar
• Ho GY, Woodward N, Coward JI. (2016). Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies. Crit Rev Oncol Hematol 102:37–46.
   PubMed Web of Science ®Google Scholar
• Huang J, Ding W, Zhu X, et al. (2022). Ligand evolution in the photoactivatable platinum(IV) anticancer prodrugs. Front Chem 10:876410.
   PubMed Web of Science ®Google Scholar
• Ibrahim A, Hirschfeld S, Cohen MH, et al. (2004). FDA drug approval summaries: oxaliplatin. Oncologist 9:8–12.
   PubMed Web of Science ®Google Scholar
• Ito H, Yamaguchi H, Fujikawa A, et al. (2012). A full validated hydrophilic interaction liquid chromatography-tandem mass spectrometric method for the quantifification of oxaliplatin in human plasma ultrafiltrates. J Pharmaceut Biomed 71:99–103.
   PubMed Web of Science ®Google Scholar
• Johnstone TC, Suntharalingam K, Lippard SJ. (2016). The next generation of platinum drugs: targeted Pt(II) agents, nanoparticle delivery, and Pt(IV) prodrugs. Chem Rev 116:3436–86.
   PubMed Web of Science ®Google Scholar
• Kelland L. (2007). The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7:573–84.
   PubMed Web of Science ®Google Scholar
• Kenny RG, Chuah SW, Crawford A, et al. (2017). Platinum (IV) prodrugs: a step closer to Ehrlich’s vision? Eur J Inorg Chem 2017:1596–612.
   Google Scholar
• Khor SY, Hu J, McLeod VM, et al. (2016). The pharmacokinetics and biodistribution of a 64 kDa PolyPEG star polymer after subcutaneous and pulmonary administration to rats. J Pharm Sci 105:293–300.
   PubMed Web of Science ®Google Scholar
• Lang TT, Li NN, Zhang J, et al. (2021). Prodrug-based nano-delivery strategy to improve the antitumor ability of carboplatin in vivo and in vitro. Drug Deliv 28:1272–80.
   PubMed Web of Science ®Google Scholar
• Ling X, Chen X, Riddell IA, et al. (2018). Glutathione-scavenging poly(disulfide amide) nanoparticles for the effective delivery of Pt(IV) prodrugs and reversal of cisplatin resistance. Nano Lett 18:4618–25.
   PubMed Web of Science ®Google Scholar
• Miller MA, Zheng YR, Gadde S, et al. (2015). Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug. Nat Commun 6:8692.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Mazumdar M, Gulati SC, et al. (1993). Phase-II trial of high-dose carboplatin and etoposide with autologous bone-marrow transplantation in 1st-line therapy for patients with poor-risk germ-cell tumors. J Natl Cancer Inst 85:1828–35.
   PubMed Web of Science ®Google Scholar
• Oun R, Moussa YE, Wheate NJ. (2018). The side effects of platinum-based chemotherapy drugs: a review for chemists. Dalton Trans 47:6645–53.
   PubMed Web of Science ®Google Scholar
• Pasut G, Veronese FM. (2009). PEG conjugates in clinical development or use as anticancer agents: an overview. Adv Drug Deliv Rev 61:1177–88.
   PubMed Web of Science ®Google Scholar
• Rudmann DG, Alston JT, Hanson JC, et al. (2013). High molecular weight polyethylene glycol cellular distribution and PEG-associated cytoplasmic vacuolation is molecular weight dependent and does not require conjugation to proteins. Toxicol Pathol 41:970–83.
   PubMed Web of Science ®Google Scholar
• Song XQ, Liu RP, Wang SQ, et al. (2020). Anticancer melatplatin prodrugs: high effect and low toxicity, MT1-ER-target and immune response in vivo. J Med Chem 63:6096–106.
   PubMed Web of Science ®Google Scholar
• Song XQ, Ma ZY, Wu YG, et al. (2019). New NSAID-Pt(IV) prodrugs to suppress metastasis and invasion of tumor cells and enhance anti-tumor effect in vitro and in vivo. Eur J Med Chem 167:377–87.
   PubMed Web of Science ®Google Scholar
• Wang Q, Xiao M, Wang DY, et al. (2021). In situ supramolecular self-assembly of Pt(IV) prodrug to conquer cisplatin resistance. Adv Funct Mater 31:2101826.
   Web of Science ®Google Scholar
• Wang L, Huang J, Chen H, et al. (2017). Exerting enhanced permeability and retention effect driven delivery by ultrafine iron oxide nanoparticles with T(1)-T(2) switchable magnetic resonance imaging contrast. ACS Nano 11:4582–92.
   PubMed Web of Science ®Google Scholar
• Wang XH, Li M, Ren KB, et al. (2020). On-demand autophagy cascade amplification nanoparticles precisely enhanced oxaliplatin-induced cancer immunotherapy. Adv Mater 32:2002160.
   PubMed Web of Science ®Google Scholar
• Wang ZG, Kuang GZ, Yu ZQ, et al. (2019). Light-activatable dual prodrug polymer nanoparticle for precise synergistic chemotherapy guided by drug-mediated computed tomography imaging. Acta Biomater 94:459–68.
   PubMed Web of Science ®Google Scholar
• Xiao HH, Noble GT, Stefanick JF, et al. (2014). Photosensitive Pt(IV)–azide prodrug-loaded nanoparticles exhibit controlled drug release and enhanced effificacy in vivo. J Control Release 173:11–17.
   PubMed Web of Science ®Google Scholar
• Xu C, Wang Y, Guo Z, et al. (2019). Pulmonary delivery by exploiting doxorubicin and cisplatin co-loaded nanoparticles for metastatic lung cancer therapy. J Control Release 295:153–63.
   PubMed Web of Science ®Google Scholar
• Xu ZW, Li QD, Zhang C, et al. (2022). Amorphous ferric oxide-coating selenium core–shell nanoparticles: a self-preservation Pt(IV) platform for multi-modal cancer therapies through hydrogen peroxide depletion-mediated anti-angiogenesis, apoptosis and ferroptosis. Nanoscale 14:11600–11.
   PubMed Web of Science ®Google Scholar
• Yao HZ, Xu ZF, Li C, et al. (2019). Synthesis and cytotoxic study of a platinum(IV) anticancer prodrug with selectivity toward luteinizing hormone-releasing hormone (LHRH) receptor-positive cancer cells. Inorg Chem 58:11076–84.
   PubMed Web of Science ®Google Scholar
• Zhang LW, Qian M, Cui HY, et al. (2021). Spatiotemporal concurrent liberation of cytotoxins from dualprodrug nanomedicine for synergistic antitumor therapy. ACS Appl Mater Interfaces 13:6053–68.
   PubMed Web of Science ®Google Scholar